Myeloma clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

    open to eligible people ages 18 years and up

    A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

    at UCSF

Our lead scientists for Myeloma research studies include .

Last updated: